[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know",
    "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $104.90, marking a -0.74% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=b872e407f22e1ff88903ba07e51fee791debe2b10f6c21da04d0ce0938fec122",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744840815,
      "headline": "Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know",
      "id": 133942629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $104.90, marking a -0.74% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=b872e407f22e1ff88903ba07e51fee791debe2b10f6c21da04d0ce0938fec122"
    }
  },
  {
    "ts": null,
    "headline": "Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?",
    "summary": "At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.",
    "url": "https://finnhub.io/api/news?id=d56e11278c5896d810bf4f8e4e2ed3a5532c24606bbc5f9e9bc98a8fe65a8039",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744823100,
      "headline": "Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?",
      "id": 133942630,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.",
      "url": "https://finnhub.io/api/news?id=d56e11278c5896d810bf4f8e4e2ed3a5532c24606bbc5f9e9bc98a8fe65a8039"
    }
  },
  {
    "ts": null,
    "headline": "Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?",
    "summary": "We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a look at where Gilead Sciences Inc. (NASDAQ:GILD) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined ‘The Exchange’ on […]",
    "url": "https://finnhub.io/api/news?id=8c0f7ecedce17f27476b2b28337e0149df46da796731d994211dc23a057f5416",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744811662,
      "headline": "Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?",
      "id": 133935760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a look at where Gilead Sciences Inc. (NASDAQ:GILD) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined ‘The Exchange’ on […]",
      "url": "https://finnhub.io/api/news?id=8c0f7ecedce17f27476b2b28337e0149df46da796731d994211dc23a057f5416"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=756a0bb04b6e4fd1aa69bebad2c8d4c9a7408d153d95d5105bb68719b960a96e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744808410,
      "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
      "id": 133935761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=756a0bb04b6e4fd1aa69bebad2c8d4c9a7408d153d95d5105bb68719b960a96e"
    }
  },
  {
    "ts": null,
    "headline": "Dodge & Cox Balanced Fund Q1 2025 Shareholder Letter",
    "summary": "Dodge & Cox Balanced Fund Q1 2025 Shareholder Letter",
    "url": "https://finnhub.io/api/news?id=116465baaa0319b1d71f77d16fc927c06f43fb76ad07d72b2ec0d1e4546ec53b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744788000,
      "headline": "Dodge & Cox Balanced Fund Q1 2025 Shareholder Letter",
      "id": 133933650,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=116465baaa0319b1d71f77d16fc927c06f43fb76ad07d72b2ec0d1e4546ec53b"
    }
  },
  {
    "ts": null,
    "headline": "Dodge & Cox Stock Fund Q1 2025 Shareholder Letter",
    "summary": "The S&P 500 fell 4.3% in the first quarter of 2025, resulting in the worst quarterly performance for U.S. equities in more than two years. Read more here.",
    "url": "https://finnhub.io/api/news?id=3b36bd202071d59c3366efcb2fc53db7f36b92bb9606d532d509f320e406ed9f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744782900,
      "headline": "Dodge & Cox Stock Fund Q1 2025 Shareholder Letter",
      "id": 133933171,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159126735/image_2159126735.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The S&P 500 fell 4.3% in the first quarter of 2025, resulting in the worst quarterly performance for U.S. equities in more than two years. Read more here.",
      "url": "https://finnhub.io/api/news?id=3b36bd202071d59c3366efcb2fc53db7f36b92bb9606d532d509f320e406ed9f"
    }
  }
]